Cargando…

COVID-19 in a patient with idiopathic pulmonary fibrosis successfully treated with Ruxolitinib

Detalles Bibliográficos
Autores principales:	Caradec, E., Mouren, D., Zrounba, M., Azoulay, L.-D., Blandin, C., Ivanoff, S., Levy, V., Brillet, P.-Y., Nunes, H., Uzunhan, Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Masson SAS. 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7647390/ https://www.ncbi.nlm.nih.gov/pubmed/33242734 http://dx.doi.org/10.1016/j.resmer.2020.100799

Ejemplares similares

Myelodysplastic syndromes and idiopathic pulmonary fibrosis: a dangerous liaison
por: Papiris, Spyros A., et al.
Publicado: (2019)

How many patients with idiopathic pulmonary fibrosis are there in Brazil?
por: Baddini-Martinez, José, et al.
Publicado: (2015)

Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis
por: Hirano, Anna, et al.
Publicado: (2017)

Cellular Senescence in Idiopathic Pulmonary Fibrosis
por: Kellogg, D. L., et al.
Publicado: (2021)

Gender Differences in Idiopathic Pulmonary Fibrosis: Are Men and Women Equal?
por: Sesé, Lucile, et al.
Publicado: (2021)

Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis
por: Costabel, Ulrich, et al.
Publicado: (2019)

Monocyte as a prognostic marker in patients with idiopathic pulmonary fibrosis
por: Zhu, Shiping
Publicado: (2021)

Coccidioidomycosis in Patients Treated With Ruxolitinib
por: Kusne, Yael, et al.
Publicado: (2020)

A case of trichodysplasia spinulosa related to ruxolitinib treated successfully with oral acitretin
por: Rosa‐Nieves, Priscilla M., et al.
Publicado: (2023)

Recalcitrant Hailey-Hailey disease successfully treated with topical ruxolitinib cream and dupilumab
por: Khang, Juna, et al.
Publicado: (2023)

Coexistence of BCR/ABL1-positive chronic myeloid leukemia and JAK2 V617F-mutated myelofibrosis successfully treated with dasatinib and ruxolitinib
por: Yi, Jun Ho, et al.
Publicado: (2019)

Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis
por: Verstovsek, S, et al.
Publicado: (2016)

Ruxolitinib therapy and telomere length in myelofibrosis
por: Caocci, G, et al.
Publicado: (2016)

Idiopathic pulmonary fibrosis can be a transient diagnosis
por: de Oliveira, Martina Rodrigues, et al.
Publicado: (2016)

Ruxolitinib inhibits cytokine production by human lung macrophages without impairing phagocytic ability
por: Mantov, Nikola, et al.
Publicado: (2022)

Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
por: Maher, Toby M., et al.
Publicado: (2019)

Perspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis
por: Yang, Xudan, et al.
Publicado: (2023)

Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis
por: Molyneaux, Philip L., et al.
Publicado: (2017)

Increased circulating desmosine and age-dependent elastinolysis in idiopathic pulmonary fibrosis
por: de Brouwer, Bart, et al.
Publicado: (2018)

The world is not enough – the value of increasing registry data in idiopathic pulmonary fibrosis
por: Moor, C. C., et al.
Publicado: (2020)

Idiopathic pulmonary fibrosis mortality in the Italian epicenter of COVID-19 pandemic
por: Faverio, P., et al.
Publicado: (2023)

Successful treatment of alopecia totalis with ruxolitinib in a preadolescent patient
por: Peterson, Danielle M., et al.
Publicado: (2020)

Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications
por: Kelly, Bryan T., et al.
Publicado: (2021)

Idiopathic pulmonary fibrosis
por: Meltzer, Eric B, et al.
Publicado: (2008)

Idiopathic Pulmonary Fibrosis
por: Lynch, Joseph P., et al.
Publicado: (2011)

Ruxolitinib Alleviates Renal Interstitial Fibrosis in UUO Mice
por: Bai, Yu, et al.
Publicado: (2020)

Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis
por: Ren, Hui, et al.
Publicado: (2017)

Evaluation of Ruxolitinib versus Best Available Therapy in Treating Primary Myelofibrosis
por: Hasan, Kawa M., et al.
Publicado: (2022)

Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Viewer or Actor? To Treat or Not to Treat?
por: Ruaro, Barbara, et al.
Publicado: (2022)

Epstein-Barr virus gastric ulcer associated with ruxolitinib
por: Kusano, Yoshiharu, et al.
Publicado: (2016)

Klebsiella pneumoniae primary liver abscess associated with ruxolitinib
por: Kusano, Yoshiharu, et al.
Publicado: (2016)

Comment on “Analysis of Microarray-Identified Genes and MicroRNAs Associated with Idiopathic Pulmonary Fibrosis”
por: Li, Chenyu, et al.
Publicado: (2018)

Coronavirus disease 2019 pneumonia may present as an acute exacerbation of idiopathic pulmonary fibrosis
por: Lee, Yong Hoon, et al.
Publicado: (2020)

Case of Pulmonary Extramedullary Hematopoiesis Responding to Ruxolitinib
por: Fujimoto, Ayumi, et al.
Publicado: (2022)

Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis
por: Bargagli, Elena, et al.
Publicado: (2020)

Hospitalizations in patients with idiopathic pulmonary fibrosis
por: Kim, Hyun J., et al.
Publicado: (2021)

Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib
por: Zhou, A, et al.
Publicado: (2015)

Idiopathic erythema annulare centrifugum successfully treated with doxycycline: A viable therapeutic option?
por: Fidanzi, Cristian, et al.
Publicado: (2023)

Chronic mucocutaneous candidiasis, pancytopenia, and systemic mycosis in a patient with STAT1 gene mutation ineffectively treated with ruxolitinib
por: Bazan-Socha, Stanisława, et al.
Publicado: (2022)

Successful Allogeneic Stem Cell Transplantation with Ruxolitinib Maintenance Therapy for CSF3R T618I Mutant Chronic Neutrophilic Leukemia
por: Ye, Peipei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pp1gamdng1r97jg8em1gslh8hc